When reviewing R&D spending trends for 2023, Merck & Co. is a clear outlier given its decision to count its $10.3 billion Prometheus acquisition as an R&D charge. In all, the company committed more than half of its revenue to R&D. But Swiss giants Roche and Novartis remain frontrunners in terms of their pipeline of…
Accelerating biologics R&D with unified software and data flows
Biologics are changing the way we treat disease, affecting where companies invest and, most importantly, impacting patients’ lives. Last year, nearly half of the 37 new drugs approved by FDA’s Center for Drug Evaluation and Research (CDER) were biologics. Its partner agency — the agency’s Center for Biologics Evaluation and Research (CBER)—approved a dozen additional…